Medicine
Blenrep 50 mg/mL powder for injection
Blenrep 50 mg/mL powder for injection is a prescription medicine containing Belantamab mafodotin for intravenous use, marketed by GlaxoSmithKline, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians. It ships in a temperature-controlled cold chain.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Cold chain
Store vials refrigerated at 36ºF to 46ºF (2ºC to 8ºC).
Key facts
- Active ingredient (INN)
- Belantamab mafodotin
- Brand
- Blenrep
- Strength
- 50 mg/mL
- Dosage form
- Powder for injection
- Route
- Intravenous
- Packs
- 1 vial
- Marketing authorisation holder
- GlaxoSmithKline
- Manufacturer
- GlaxoSmithKline
- Origin register
- US FDA, United States
- Storage
- Store vials refrigerated at 36ºF to 46ºF (2ºC to 8ºC).
- Cold chain
- Yes, shipped temperature controlled
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- L01FX15 Belantamab mafodotin
- HS code (indicative)
- 3002.15Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 23 October 2025
- Identifiers
- RxCUI 2725585, 2725587DailyMed set ID aef7c34c-fef8-407c-99c0-a68aded53c60NDC 0173-0913Application BLA761440
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 1 vial in 1 carton / 1.4 mL in 1 vial | 0173-0913-01 | GlaxoSmithKline | 23 October 2025 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Clinical summary
Belantamab mafodotin is a prescription medicine indicated in combination with bortezomib and dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least two prior lines of therapy. MedsAcross supplies Belantamab mafodotin for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about Belantamab mafodotinFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Blenrep prescribing information (GlaxoSmithKline) · U.S. National Library of Medicine, DailyMed
- Blenrep: European public assessment report (EPAR) · European Medicines Agency
Need Blenrep 50 mg/mL powder for injection for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.